DexCom, Inc. Q3 2025 Earnings Recap

DXCM Q3 2025 November 1, 2025

Get alerts when DXCM reports next quarter

DexCom reported strong third-quarter 2025 results with 20% organic revenue growth, driven by expanding customer access and innovative product offerings in the continuous glucose monitoring (CGM) space.

Earnings Per Share Beat

$0.61 vs $0.58 est.

+5.9% surprise

Revenue Beat

1209300000 vs 1183740072 est.

+2.2% surprise

Market Reaction

1-Day +0.0%

5-Day +1.82%

30-Day +5.96%

See DXCM alongside your other holdings

Add to your portfolio — free

Key Takeaways

Achieved 20% organic revenue growth year-over-year, reflecting robust market demand and competitive positioning.
Expanded CGM access to nearly 6 million U.S. type 2 diabetes patients, targeting full coverage for over 25 million individuals.
Introduced DexCom Smart Basal, an innovative titration module designed to enhance basal insulin management and improve patient adherence.
Stelo product surpassed $100 million in revenue within its first year, indicating strong market traction and consumer interest in CGM for metabolic health.
Continued advancement of G7 15-day system rollout, bolstered by successful reimbursement strategies.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit DXCM on AllInvestView.

Previous Q2 2025

Next Q1 2026